---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-278717"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:43:08.409558+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Candel prices $80M public offering of common stock and pre-funded warrants at $6.00/share

## Summary
- Offering: 10,000,001 common shares at $6.00/share plus pre-funded warrants for 3,333,333 shares at $5.99/warrant.
- Gross proceeds ~$80M; net proceeds ~$74.7M (or ~$86M if underwriters' 2M-share option is exercised).
- Proceeds to fund development, including BLA submission for CAN-2409 in prostate cancer, and general corporate purposes.
- Cash runway extended into Q1 2027; key data readouts expected in NSCLC/PDAC (Q1 2025) and recurrent glioblastoma (Q4 2025).
- Offering expected to close Dec 16, 2024; joint bookrunners: Citigroup, BofA Securities, Canaccord Genuity.

## SEC filing metadata
- accession: 0001193125-24-278717
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312524278717/0001193125-24-278717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312524278717/d859956d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-278717
- JSON: https://secwatch.observer/filing/0001193125-24-278717.json
- Plain text: https://secwatch.observer/filing/0001193125-24-278717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.